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While several prognostic factors have been identified
in breast carcinoma, the clinical outcome remains
hard to predict for individual patients. Better predic-
tive markers are needed to help guide difficult treat-
ment decisions. In a previous study of 78 breast car-
cinoma specimens, we noted an association between
poor clinical outcome and the expression of cytoker-
atin 17 and/or cytokeratin 5 mRNAs. Here we describe
the results of immunohistochemistry studies using
monoclonal antibodies against these markers to ana-
lyze more than 600 paraffin-embedded breast tumors
in tissue microarrays. We found that expression of
cytokeratin 17 and/or cytokeratin 5/6 in tumor cells
was associated with a poor clinical outcome. More-
over , multivariate analysis showed that in node-
negative breast carcinoma, expression of these
cytokeratins was a prognostic factor independent
of tumor size and tumor grade. (Am J Pathol 2002,
161:1991–1996)
A number of parameters are used to predict the clinical
outcome of breast carcinoma, and to guide treatment
decisions accordingly. The most important prognostic
factors in current use are clinical features such as lymph
node (LN) status, tumor size, and tumor grade. The ex-
pression level and staining patterns of several proteins
are also useful in predicting which tumors will respond to
specific therapies; tamoxifen is used to treat only estro-
gen receptor-positive tumors and herceptin to treat Her2/
neu overexpressing tumors. Although these histological
prognosticators are undeniably useful, the clinical course
of any individual patient with breast carcinoma remains
difficult to predict. There is little doubt that there is still
considerable molecular heterogeneity within the existing
tumor categories. Many studies have continued to iden-
tify and explore molecular markers that might help to
better stratify patients. In multivariate analysis, however,
many of these factors co-vary and are therefore not in-
dependently informative.1,2
With the development of DNA microarray technologies
for large-scale analysis of gene expression patterns, a
systematic genome-wide search for molecular markers in
breast carcinoma has become possible.3–5 We recently
analyzed genomic expression patterns in 78 frozen
breast carcinoma specimens using DNA microarrays.6
This study revealed at least five groups of patients that
could be distinguished on the basis of their global gene
expression patterns. Two traditional markers, Her2/neu
and the estrogen receptor, and a group of cytokeratin
genes, were notable for their differential expression
among the breast cancer subgroups. Analysis of the
survival data in the study showed that two subgroups had
a significantly poorer prognosis; one was characterized
by elevated expression of Her2/neu, the other was char-
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acterized by high levels of expression of genes charac-
teristic of the basal epithelial cells of the normal mam-
mary gland, including the genes that encode cytokeratins
17 and 5. The number of cases in the DNA microarray
study was too small to allow multivariate analysis.
To further explore the clinical significance of these
findings, we used the recently developed technique of
tissue microarrays (TMA) in a retrospective immunohis-
tochemistry evaluation of 611 breast tumor samples.7,8
This approach allowed us to evaluate protein expression
in hundreds of tumors at once, with a single staining
reaction on a single glass slide. Using commercially avail-
able antibodies against cytokeratins 17 and 5/6, we carried
out an immunohistochemical assay for these markers on
samples from more than 600 breast carcinomas.
Materials and Methods
Tissue Microarrays
A total of 611 different paraffin-embedded breast carci-
noma samples were identified in the files in the Depart-
ment of Pathology at the University of Basel, Women’s
Hospital Rheinfelden, and the Kreiskrankenhaus Lorrach.
The specimens were obtained from patients who under-
went surgery in the period between 1985 and 1994. The
histological parameters for all cases were reviewed by a
single pathologist (J.T.) and the histological type and
grade was determined for each case according to Elston
and Ellis.9 Follow-up was obtained for 553 cases and
ranged from 1 to 151 months, with a mean of 65.9
months. The use of these specimens and data for re-
search purposes was approved by the Ethics Committee
of the Basel University Hospital. After surgery, 303 pa-
tients received additional systemic therapy (193 patients
received hormonal therapy, 57 patients received chemo-
therapy, and 53 received combined hormonal and che-
motherapy). Tissue microarrays were constructed by ob-
taining 0.6-mm diameter tissue cores from each tumor
and placing these cores in a new paraffin block in rows
and columns.7,8,10,11 Each of the 611 cases was sampled
twice, once from the center of the tumor, and once from
the periphery of the mass. Cores taken from the central
area from each case were combined in one array and
cores taken from the periphery of the tumor were com-
bined in a second array. A more detailed description of
these breast carcinoma tissue microarrays, demonstrat-
ing the reliability of these arrays for correlating clinical
outcome with expression of a variety of markers (includ-
ing estrogen receptor, progesterone receptor, Her2/neu
[ErbB2], and p53), and including more clinical informa-
tion, has been published previously.7,8
Immunohistochemistry and Scoring
Double-staining of normal breast epithelium and tumors
in conventional paraffin sections was performed by first
staining luminal cells with CAM5.2 using alkaline phos-
phatase/fast blue staining and subsequent staining of
basal cells with CK17 using horseradish peroxidase/DAB
staining. Sections of tissue microarrays were stained with
monoclonal antibodies specific for cytokeratin 17 (DAKO,
Carpenteria, CA, clone E3, dilution 1:10) and cytokeratin
5/6 (Boehringer Mannheim, Indianapolis, IN, dilution
1:10) after antigen retrieval by microwave treatment in
citrate buffer.12 Staining results were scored as follows:
1, invasive tumor cells present in tissue core and no
staining seen; 2, invasive tumor cells present and weak
staining; 3, invasive tumor cells present with strong stain-
ing. Only those cores showing invasive carcinoma were
included in the outcome analysis. Cases that either had
no tissue present on the array sections or cases in which
the material sampled consisted only of fat, fibrosis, nor-
mal mammary glands, or in situ carcinoma, were omitted
from further analysis. Immunohistochemical staining for
cytokeratins either in tissue microarray samples or con-
ventional paraffin sections, often produced only focal
staining of tumor cells. To account for the focal expres-
sion of CK17 and CK5/6, each of the 611 breast tumors
was analyzed four times: with anti-CK17 and anti-CK5/6
antibody on the “central sample” array, and with anti-
CK17 and anti-CK5/6 antibody on the “peripheral sam-
ple” array. A breast tumor sample was scored as staining
positive for the keratins if infiltrating carcinoma in one or
more of the cores from that sample reacted with either of
the antibodies. To aid in recognizing infiltrating carci-
noma in the core samples, sections of each array were
also stained with a cytokeratin mix reacting with cytoker-
atins 8 and 18 (CAM5.2, Becton Dickinson, Franklin
Lakes, NJ, dilution 1:20) after antigen unmasking by tryp-
sin digestion to highlight invasive carcinoma cells. Sec-
tions of arrays were also stained with antibodies against
estrogen receptor (Ventana, Tuscon, AZ), Her2/neu
(DAKO), and GATA-3 (Santa Cruz Biotechnology, Santa
Cruz, CA). Scoring for Her2/neu was performed following
FDA approved manufacturer’s instructions. Nuclear
staining was scored for estrogen receptor (ER) and
GATA-3 staining, with tumors with less than 5% nuclear
staining scored as negative, those with 5 to 20% staining
as weak, and those with more than 20% staining scored
as strongly positive.
Rabbit Antiserum
A rabbit polyclonal antiserum was raised by injecting
three peptides derived from cytokeratin 17 protein se-
quence. The peptides were synthesized by standard
9-fluorenylmethloxcarbonyl (FMOC) chemistry: peptide 1
KKEPVTTRQVRTIVEE, peptide 2 QDGKVISSREQVHQ-
TTR, peptide 3 SSSIKGSSGLGGGSS. The peptides were
conjugated to keyhole limpet hemocyanin (KLH). The
peptide-KLH conjugate was injected into two out-bred
rabbits. The serum was harvested after the rabbits dem-
onstrated significant anti-peptide titer. Affinity-purified
antiserum was obtained by binding the antiserum to an
affinity column conjugated with the three peptides; the
bound antibodies were eluted with a pH gradient.
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Statistical Analysis
Univariate (Kaplan-Meier) analysis of patient survival for
subgroups defined on the basis of cytokeratin expression
was performed using WinSTAT software (www.winstat.
com). Subsequent multivariate analyses were performed
using Cox’s proportional hazards model for survival data.13
Results
Basal Keratin Staining in Normal Breast and
Breast Carcinoma
In normal breast, CK17 and CK5/6 stain the basal layer of
breast ductal epithelium while keratins 8 and 18 stain
luminal cells (Figure 1A). An examination of whole paraf-
fin sections of breast carcinoma showed that cytokeratin
17 and 5/6 expression in paraffin-embedded tissue,
when present, was focal (Figure 1B) with often less than
10% of tumor cells reacting. To further investigate the
focal reactivity of the monoclonal antibodies against
the basal-type cytokeratins, and as an attempt to im-
prove the reliability of this test, we raised a rabbit
antiserum against CK17. This antiserum was tested
using a separate tissue microarray with over 300 hun-
dred breast samples (M. van de Rijn, unpublished
results). The new antiserum and the monoclonal anti-
body against CK17 showed very similar reactivity with
epithelial cells in the breast sections. Both reagents
stained the same fraction of tumor cells suggesting
that neither is a significantly better reagent (data not
shown). These results suggest that the focal reactivity
seen with monoclonal anti-CK17 was not due to weak
reactivity of the monoclonal antibody but to the expres-
sion of this basal keratin in only a subset of tumor cells
at a level detectable by immunohistochemistry.
Analysis of Basal Keratin Expression in Breast
Carcinoma Using Tissue Microarrays
Because the individual tumor samples examined in tissue
microarray cores were significantly smaller than those in
conventional tissue sections, we were concerned that the
focal reactivity of basal type cytokeratins might cause
positive tumors to be missed. We decided to maximize
the chance of detecting basal keratin expression in the
breast tumors on the arrays by staining them with mono-
clonal antibodies directed at both CK5/6 and CK17 and
by examining arrays made with cores taken from both
central and peripheral areas of the tumors. By combining
the results from the “central” array and the “peripheral”
array, 532 tumors were available for CK17 analysis, 535
were available for CK5/6 analysis, and 564 were available
for either CK17 or CK5/6. The remainder of the tumors
represented on the arrays were either lost in transfer
during sectioning of the tissue microarray block, or
showed no convincing invasive carcinoma in the sections
we examined. After combining results from the peripheral
and central microarrays, 75 and 63 tumors scored posi-
tive (either weak or strongly) for CK17 and CK5/6, re-
spectively. By combining the results from the stains for
CK17 and CK5/6, 90 cases (16%) of the 564 tumors
examined reacted with either CK17 and/or CK5/6. Of
these 90 cases, 51 stained for both antibodies, while the
remainder reacted with either of the two antibodies. Fol-
low-up data were available for 505 of the 564 cases on
which CK staining data were obtained. The follow-up
period ranged from 1 to 151 months with a mean of 65.9
months and a median of 63 months.
Kaplan-Meier survival analysis for all patients with fol-
low-up showed that the absence of detectable cytokera-
tin 17 or cytokeratin 5 was associated with a significantly
better prognosis than the presence of either of these
cytokeratins (Figure 2A, P  0.012). The lymph node
status was known in 474 patients. In the group of 229
patients with known lymph node metastases, the expres-
sion of CK17 and CK5/6 had no predictive value. In
contrast, in the group of 245 patients without lymph node
metastases at presentation, CK17 and/or CK5/6 expres-
sion was associated with significantly shorter survival
(Figure 2B, P  0.006). The percentage of basal keratin-
positive tumors was similar in patients with and without
lymph node metastases. Multivariate analysis on all pa-
tients taken together showed that the prognostic associ-
ation of basal cytokeratin expression with poor outcome
Figure 1. A: Normal mammary gland simultaneously stained with CAM5.2 monoclonal antibody [specific for keratins 8 and 18] (blue), and monoclonal
anti-cytokeratin 17 (brown). Note that the CAM5.2 antibody specifically stains the lumenal epithelial cells, while the anti-cytokeratin 17 antibody specifically stains
the basal epithelial cells of the normal mammary duct. B: Whole paraffin section of breast carcinoma stained with CAM5.2 monoclonal antibody (blue), and
monoclonal anti-cytokeratin 17 (brown). Note the focal staining pattern for cytokeratin 17.
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was not independent from tumor size, LN status, and
histological grade. When only patients who presented
without lymph node metastases were considered, how-
ever, the expression of basal cytokeratins was not only a
significant prognostic factor, but its prognostic signifi-
cance was independent of tumor size, tumor grade,
Her2/neu status, ER status, and GATA-3 status.
Her2/neu, Estrogen Receptor and GATA-3
Staining on Breast Carcinoma Arrays
Sections of the tissue microarrays made with peripheral
cores were stained for estrogen receptor and Her2/neu.
As expected, expression of estrogen receptors was as-
sociated with a better clinical outcome. This finding was
independent of tumor grade, LN status, and size (data
not shown). In contrast, Her2/neu expression was asso-
ciated with a poor prognosis. These results are compat-
ible with previous reports and are similar to those of two
prior studies7,8 conducted using the same breast tumor
tissue microarrays used here. We also stained sections of
the arrays with antibodies specific for GATA-binding pro-
tein 3, a protein that has previously been observed to be
co-expressed with the estrogen receptor.14 Expression of
GATA-3 was associated with a good clinical outcome,
and highly correlated (2  720.3 on 9 degrees of free-
dom) with estrogen receptor expression. Our immunohis-
tochemical staining results for estrogen receptor,
GATA-3, and Her2/neu thus confirm results of prior stud-
ies, and provide further evidence of the utility and reli-
ability of tissue microarray-based studies. A comparison
was made between the basal cytokeratin staining and
Her2/neu staining on 304 tumors for which both cytoker-
atin and Her2/neu staining data were available. As shown
in Table 1, no statistically significant correlation was
found between basal cytokeratin staining and Her2/neu
expression, a finding further confirmed by our multivari-
ate analysis (above).
Discussion
The sequencing of the human genome and the develop-
ment of massively parallel technologies for analyzing
gene expression have opened a new era of molecular
diagnostic medicine. DNA microarray analysis now al-
lows the rapid determination of mRNA levels for many
thousands of genes in tumor samples while tissue mi-
croarrays can be used to analyze large numbers of tu-
mors by immunohistochemical or other staining methods.
In a previous study we examined the molecular profiles of
breast carcinomas from 42 patients using DNA microar-
rays representing more than 8000 genes.15 That study
identified a subset of carcinomas that was distinguished
from the other tumors by their relatively high level of
expression of a specific set of genes characteristic of the
basal epithelial cells of normal mammary ducts. Basal
keratin expression distinguished this set of tumors from
the majority of the tumor samples, which expressed ker-
atin types typically expressed in normal luminal breast
epithelial cells. A subsequent study on a larger group of
78 breast tumors showed that the carcinomas in which
these “basal” keratins were expressed had a significantly
poorer prognosis.1
Using tissue microarrays made with over 600 breast
carcinoma cases, we show here that the presence of
basal epithelial cytokeratins in breast carcinoma cells is
associated with a poor prognosis. Because of the rela-
tively small size of the tissue samples available for anal-
ysis in tissue microarrays, the interpretation of stains that
are only focally or heterogeneously reactive can be am-
biguous. This was a special concern in our study, be-
Figure 2. A: Kaplan-Meier survival curve showing poor outcome in cytoker-
atin 17- and/or 5/6-positive tumors (P  0.012). Clinical follow-up was
available for 505 patients (mean, 65.9 months). A: No expression of CK17 or
cytokeratin 5/6 in tumor cells. B: Expression of CK17 and/or cytokeratin 5/6
in tumor cells. B: The effect of cytokeratin 17 and/or cytokeratin 5/6 expres-
sion in 245 patients with negative lymph nodes (P 0.006). The lymph node
status was known in 474 patients. Patients expressing basal keratin (B) in this
group have worse outcome than in patients without expression of these
markers (A). Multivariate analysis showed that this effect was independent of
tumor size, tumor grade, or Her2neu, ER, or GATA-3 expression.
Table 1. Comparison of Her2-Neu and Cytokeration Staining
Results
her2 her
ck 40 9
ck 200 55
No significant correlation between cytokeratin expression and
Her2neu expression could be found on 304 cases (Chi squared, P 
0.615) stained with both markers.
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cause the expression of basal keratins, as detected by
immunohistochemical staining, is often very localized,
with only scattered tumor cells in a cross-section of the
tumor mass showing detectable reactivity. To minimize
this ambiguity, we combined results from samples taken
from two different areas (central and peripheral) of each
tumor, and stained samples from each site with two dif-
ferent antibodies (anti-CK17 and anti-CK5/6). Sixteen
percent of the tumors we examined expressed detect-
able CK17 and/or CK5/6. This frequency was similar to
that found in an independent patient population, in which
high levels of mRNA for cytokeratins 5 and 17 were
detected in 18% of the breast carcinomas studied. In
both studies the expression of these markers was asso-
ciated with poor clinical outcome.6,15
Because of the large number of patient samples that
we were able to analyze using tissue microarrays, we
were able to test separately the prognostic significance
of these markers in patients with lymph node metastases
and those without evident metastases. In patients with
metastatic disease to the lymph nodes, the expression of
the basal cytokeratins was not associated with a signifi-
cant difference in clinical outcome. However, in patients
without detectable lymph node metastases, expression
of “basal” cytokeratins was associated with a poor prog-
nosis independent of tumor size, tumor grade, or immu-
nostain reactivity for ER, Her2/neu, or GATA-3. Taken
together with the DNA microarray results, these findings
support the idea that anti-cytokeratin antibodies may
identify a distinct form of breast cancer, derived from
basal cells rather than the luminal cells from which the
majority of mammary cancers appear to arise. Further
studies are needed to define the cellular origin of each of
these groups of tumors.
Two previous immunohistochemistry studies have sug-
gested a correlation between basal cell type markers and
poor prognosis. Dairkee and colleagues16 reported four
cases of breast carcinoma with expression of the marker
312C8–1 for myoepithelial cells in the tumor cells and
noted a poor clinical outcome. In a study of 51 patients
with clinical follow-up, Malzahn et al17 found a statistically
significant association of basal/myoepithelial cell keratin ex-
pression with poor prognosis. In contrast to our findings, this
association was found to be statistically significant in
LN-positive patients but not in LN-negative patients.
The interpretation of immunohistochemical staining re-
sults for the basal keratins is complicated by the focal
and often weak reactivity of monoclonal antibodies
against these proteins, limiting their use in clinical set-
tings. We have therefore begun searching for better im-
munohistochemical markers for this group of breast can-
cers. We considered the possibility that alternative
antibodies against these cytokeratins might provide bet-
ter performance. Analysis of more than 300 breast carci-
noma samples in a separate array showed that the num-
ber of staining cells, the focal staining pattern, and the
intensity of staining were similar for a new polyclonal
antiserum against CK17 and the commercial monoclonal
antibodies. This result suggests that the basal keratins
are indeed only focally expressed at a level detectable by
immunohistochemistry and that the low numbers of cells
stained with antibodies are not due to a weak reactivity of
the monoclonal antibodies with the protein. We are cur-
rently developing antibodies specific to the products of
other genes that were found in the DNA microarray stud-
ies to be expressed specifically in the same tumors that
expressed basal keratins.
Several studies have now reported that breast cancers
expressing basal cytokeratins are not uncommon
(10%), and that they are associated with a poor prog-
nosis.1 Patients with metastatic breast carcinoma to the
axillary lymph nodes are at high risk for recurrence and
most receive adjuvant therapy. The situation for “node-
negative” patients is less clear; depending on the size
and grade of the tumor, the reported recurrence rate
varies between five and thirty percent. In patients who
present without detectable lymph-node metastases, the
clinical decision to give or withhold systemic therapy is
therefore a difficult one and hence it is for this group of
patients that the need for new prognostic markers is the
most acute. The relative size of this group of patients is
expected to increase, due to continuing advances in
screening and diagnostic techniques that allow detection
of smaller breast tumors. Most of these smaller tumors
have not metastasized to the “sentinel” lymph node. This
group of patients therefore faces a difficult choice among
a variety of treatment options, including lumpectomy,
mastectomy, chemotherapy, radiation therapy, and hor-
monal therapy. Expression of cytokeratins 17 and 5/6
appears to define a group of breast tumors with a rela-
tively high mortality rate: clearly a significant consider-
ation in the treatment decisions for node-negative breast
carcinoma patients. Whether more aggressive treatment
procedures will improve the outcome for these patients,
and which of the available options provide the greatest
benefit, is an important question for future studies. The
challenge in the future will be to develop therapies di-
rected specifically at this molecularly and clinically dis-
tinct form of breast cancer.
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